Dendreon reports survival data on Provenge

02/14/2008 | Forbes

The overall survival of prostate cancer patients taking Dendreon's experimental vaccine Provenge appears to improve when they receive more potent doses of the drug, according to data the company released Thursday. Dendreon is trying to get FDA approval for the vaccine.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL